Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors
Author:
Publisher
Edizioni Minerva Medica
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://www.minervamedica.it/pdf.php?cod=R07Y2022N03A0344
Reference79 articles.
1. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
2. Cardiovascular mortality and morbidity in type-2 diabetes mellitus
3. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2TM study
4. Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity
5. Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. NEW DIRECTIONS IN PHARMACOLOGICAL TREATMENT WITH SGLT-2 INHIBITOR MOLECULES IN THE LIGHT OF CURRENT GUIDELINES FOR DIABETES MELLITUS, HEART FAILURE AND KIDNEY DISEASE;FARMACIA;2023-08-31
2. New perspectives in management of diabetes in long-term care facilities;Minerva Endocrinology;2023-05
3. SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study;Minerva Endocrinology;2021-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3